Articles tagged with Alzheimer Disease
The GuidAge study suggests that memory complaints reported by elderly individuals can predict a decline in cognitive performance. Five specific items on the McNair and Kahn Scale were found to be statistically significant, including difficulty remembering phone numbers, appointments, and instructions.
A new Australian-led study found that aerobic exercise increases the size of the left region of the hippocampus, a critical area for memory and other brain functions. The study showed significant benefits of exercise on brain health, with implications for preventing age-related neurodegenerative disorders.
A registry-based study from Aarhus University found that heart attack survivors are at a higher risk of developing vascular dementia, which is caused by vascular damage in the brain. The risk remains elevated for up to 35 years after the heart attack, with patients who underwent bypass surgery showing a fourfold increased risk.
A study suggests that odor identification tests can identify patients with mild cognitive impairment who may benefit from cholinesterase inhibitor treatments. Short-term improvements in smell identification scores predicted longer-term cognitive improvement with donepezil treatment.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have identified a peptide that can predict early Alzheimer's disease by recognizing vasculature associated with brain inflammation. The discovery may provide a means of homing drugs to diseased areas of the brain, targeting treatments before amyloid plaques appear.
Research published in the American Thoracic Society's journal found a correlation between sleep apnea severity and an increase in amyloid deposits in the brain, which are associated with Alzheimer's disease. The study suggests that treatments for sleep apnea may delay cognitive impairment and dementia in older adults.
Researchers from RUDN University have developed a novel three-component reaction to produce complex heterocyclic compounds with antitumor and anti-Alzheimer's properties. The approach enables the efficient synthesis of these compounds, reducing waste and labor costs, and opens up new possibilities for pharmaceutical applications.
A study published in Neurology found that reduced heart blood flow may lead to lower blood flow in the brain's memory centers. The research suggests that mechanisms regulating blood flow become vulnerable with age, potentially leading to cognitive impairment.
A study published in Neurology found that older adults with lower cardiac index have reduced blood flow in the temporal lobe regions of the brain, where Alzheimer's pathology begins. This suggests a link between heart health and cognitive impairment, potentially paving the way for new treatments.
Researchers at Sanford Burnham Prebys Medical Discovery Institute identified a new protective function for the brain protein SORLA, which limits amyloid beta's toxic signaling. The study suggests that increasing levels of SORLA in mice reduced cognitive impairments caused by amyloid beta.
A neuroprotective compound has been shown to protect against nerve cell death, depression, and memory problems in a rat model of Alzheimer's disease. The treatment also prevented the development of depression-like behavior and delayed cognitive decline.
Researchers will study the effects of a multicultural healthy diet rich in anti-inflammatory foods on cognitive function and inflammation. The study aims to assess whether this diet can reduce cognitive decline and Alzheimer's disease risk in middle-aged and older participants.
Researchers found a connection between abnormal glucose breakdown in the brain and the severity of Alzheimer's symptoms, with lower glycolysis rates and higher brain glucose levels correlated to more severe pathology. The study suggests that targeting glycolysis defects could lead to new treatments for Alzheimer's disease.
The study reveals that β-amyloid accumulation occurs in the inner parts of the brain within the default mode network. This finding holds significant implications for future research studies and clinical diagnosis of Alzheimer's disease.
A new study found that SuperAgers -- people aged 80+ with exceptional cognitive ability -- report more satisfying relationships compared to their peers. This association suggests that maintaining strong social networks may be linked to slower cognitive decline.
Research suggests that chronic inflammation in mid-life may be an early contributor to brain cell loss and memory decline associated with Alzheimer's disease. The study found people with elevated inflammation biomarkers had smaller brain volumes and lower scores on a memory test compared to those without elevated markers.
Research suggests that amyloid-beta, a toxic protein, can travel to the brain from other parts of the body, contributing to Alzheimer's disease. This discovery offers hope for new drug therapies that target the kidneys or liver to prevent the protein from reaching the brain.
A clinical trial involving 311 patients with prodromal Alzheimer's found significant advantages in nutrient-treated patients, including 45% less worsening in Clinical Dementia Rating-Sum of Box. The study also showed less brain atrophy in the active group, with notable benefits for hippocampal damage and everyday tasks.
UTHealth researchers identified a key factor in mid-life cell aging that can predict Alzheimer's disease decades before symptoms appear. The study found that mice lacking IL33 gene experienced dementia at age 68, highlighting the potential of this protein as a biomarker for early detection.
Researchers found impaired mitochondrial metabolism and increased glycolysis in LOAD cells, indicating failing mitochondria. The study suggests that bioenergetics changes may contribute to the risk and pathophysiology of late-onset Alzheimer's disease.
Researchers found that some γ-secretase inhibitors, like semagacestat, cause accumulation of toxic intraneuronal Aβ instead of inhibiting its production. This discovery sheds light on the discrepancy between preclinical and clinical trial findings for Alzheimer's disease treatments.
A CAMH study found that people with early Alzheimer's disease have lower brain plasticity in the frontal lobes, leading to poorer working memory and recall ability. Researchers believe impaired brain plasticity may be a future target for treatment or prevention of dementia.
Researchers at the University of Eastern Finland found no association between long-term opioid use and Alzheimer's disease. Despite this, they highlight potential adverse effects such as drowsiness and addiction, suggesting restricted use for severe pain conditions.
A new $1.85 million grant will support a Phase 2 clinical trial of AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid, to test its effectiveness in slowing or stopping brain cell death in people with mild cognitive impairment or Alzheimer's disease.
Researchers are developing sophisticated methods to understand Alzheimer's disease mechanisms and predict its onset before symptoms appear. The five-year study aims to pinpoint factors leading to cognitive decline in relation to beta-amyloid proteins.
The VA National PTSD Brain Bank is a resource aimed at providing answers to the complex nature of posttraumatic stress disorder. The bank supports research on the causes, progression, and treatment of PTSD by storing tissue from brains of individuals with PTSD.
A study from the University of Pennsylvania sheds light on how seniors cope with results showing an elevated level of beta amyloid protein plaques, a biomarker of Alzheimer's-disease. Researchers found that many seniors are dissatisfied with the ambiguity of the message and desire more detailed information about their risk.
The University of Minnesota Medical School's Center for Magnetic Resonance Research has received a NIH R01 grant to investigate the underlying trajectory of brain chemistry in healthy aging and Alzheimer's disease. The project aims to identify abnormal metabolic pathways in Alzheimer's disease.
Scientists have characterized a new class of drugs that precisely block the production of toxic forms of beta-amyloid, a primary driver of Alzheimer's disease. Treatment with these gamma-secretase modulators reduces levels of amyloid-beta 42 in animal models and cellular systems.
Researchers will investigate brain aging and Alzheimer's using advanced bio imaging technology on a representative sample of 1,310 Tsimane adults. The project aims to understand the relationship between vascular health and Alzheimer's risk.
A new imaging system, cryo-MOST, has been developed to monitor brain changes indicative of Alzheimer's disease in mouse models. The system uses autofluorescence to image senile plaques with micron-level resolution, improving the understanding of disease progression and facilitating the development of new treatments.
Researchers discover how seizures trigger cognitive deficits in Alzheimer's disease through increased levels of the protein deltaFosB, leading to suppressed production of calbindin and disrupted brain activity. Further studies support the findings, showing potential new strategies for reducing cognitive deficits.
McGill researchers uncover a cellular mechanism contributing to communication breakdown between neurons in Alzheimer's disease. They found inadequate levels of the protein RBFOX1, which stabilizes RNAs involved in synaptic transmission, may be a factor in faulty connections characteristic of Alzheimer's.
The study highlights the growing impact of neurological disorders on global health, with increased deaths and disabilities over the past 25 years. The most prevalent disorders are tension-type headaches, migraine, and Alzheimer's disease, which have seen significant increases in cases and DALYs.
Researchers found that menopause triggers metabolic changes in the brain, increasing the risk of Alzheimer's disease. The study used PET imaging to measure glucose metabolism in the brains of 43 healthy women aged 40-60, revealing lower levels of glucose metabolism in post-menopausal women.
Researchers at the University of California, Irvine have been awarded a federal grant to develop a genetically engineered mouse model that more closely mirrors human Alzheimer's disease. The new mouse will enable superior testing of therapies designed to slow or prevent the disease, according to experts.
A new CAMH study found that people unaware of their memory loss are more likely to progress to Alzheimer's disease. Those aware of memory problems are unlikely to develop dementia. The study used PET brain scans to identify specific brain regions affected in impaired illness awareness.
M344 altered key gene expression in a cellular model of AD, preventing cognitive decline and improving memory. In mouse models, low-dose administration of M344 prevented cognitive decline and improved learning and memory.
Researchers at Goethe University Frankfurt have identified key molecules involved in regulating brain plasticity and memory. GRIP1, ephrinB2, and ApoER2 are found to interact and regulate AMPA receptor insertion at the synapse, influencing learning and memory.
Researchers discovered that LSD1 removal in adult mice induces changes in gene activity similar to Alzheimer's disease. LSD1 protein is also perturbed in human brain samples with Alzheimer's and FTD, suggesting it as a central player in these neurodegenerative diseases.
Researchers found that high-risk TREM2 variants can hobble the immune system's ability to protect against amyloid beta, but later in the disease, the absence of TREM2 protein protects the brain from damage. The study suggests targeting the TREM2 protein as a means of preventing or treating Alzheimer's may be complicated and that doctor...
Indiana University will establish a network of sites to study early-onset Alzheimer's disease, a rare variant that affects people under 65. The Longitudinal Early-onset AD Study (LEADS) aims to bridge the gap in clinical trials for this population by collecting robust longitudinal data on genetic risk factors and treatment options.
A new biomarker detects Alzheimer's disease in its preclinical phase, identifying individuals with impaired neuropsychological and neurophysiological functions. The discovery has high accuracy and sensitivity, offering a promising approach to early diagnosis and treatment.
Up to two thirds of people with Alzheimer's disease experience psychotic episodes, linked to faster cognitive decline and accelerated death rates. New approaches to clinical trials aim to develop effective non-drug interventions to alleviate symptoms without adverse outcomes.
A new study ranks the safety and effectiveness of four cognitive enhancers for Alzheimer's dementia, finding that donepezil is most likely to improve cognition. However, patients taking donepezil are more likely to experience side effects such as nausea and vomiting.
Rensselaer Polytechnic Institute has received a $1.5 million training grant from the National Institutes of Health to support a new Alzheimer's Disease Clinical and Translational Research Training Program. The program aims to develop diagnostic tools, treatments, and potentially a cure for Alzheimer's disease.
Researchers have discovered a possible biomarker, CCL11, that may allow CTE to be diagnosed in living individuals. The study found elevated CCL11 levels in the brains of former football players with CTE compared to non-athletes and those with Alzheimer's disease. This discovery could lead to targeted treatments for CTE sufferers.
A research team led by DGIST Professor Moon Cheil has identified the reason behind olfactory dysfunction in patients with early-stage Alzheimer's disease. The study reveals that a toxic protein called beta-amyloid accumulates in the peripheral nervous system, specifically in the olfactory epithelium, leading to olfactory failure.
Researchers have discovered a novel molecular pathway that interacts with prion protein, triggering neuronal dysfunction and cognitive impairments in Parkinson's disease. The study provides new targets for therapeutic intervention.
A new polygenic hazard score test combines 31 genetic variants and APOE E4 to predict Alzheimer's risk in cognitively normal older adults, outperforming traditional APOE E4 testing. The test identifies high-risk individuals with early cognitive decline and higher amyloid plaque levels.
A new $5.4 million grant to JAX will fund research on cognitive resilience to Alzheimer's disease. Understanding the genetic factors behind this resilience could lead to targets for treatment and prevention of Alzheimer's.
Researchers have discovered that the presence of ApoE4 exacerbates brain damage caused by tau tangles, leading to neurodegeneration and memory loss. Blocking ApoE4 in the brain may prevent these effects, offering a new potential therapeutic target for Alzheimer's disease.
A new study by Duke-NUS Medical School found that Alzheimer's patients with CeVD exhibit different brain network changes compared to those without CeVD, suggesting distinct underlying pathology. This finding may improve diagnosis, treatment, and management of neurodegenerative disorders.
Researchers at the University of Washington School of Medicine found that different brain areas interact to recognize partially covered shapes. The study reveals how signals from the visual cortex and thinking sections of the brain work together to enhance shape recognition.
A new study found that decreased glucose metabolism in medial prefrontal areas is associated with nutritional status in patients with prodromal and early Alzheimer's disease. The study suggests that hypometabolism in the medial prefrontal areas may explain the underlying mechanism of weight loss in AD. Decrease in fat mass was also lin...
A new study by USC researchers suggests that the TOMM40 gene, neighboring ApoE4 on chromosome 19, has a significant influence on late-life development of dementia and Alzheimer's. The research found that a TOMM40 variant was more influential than ApoE4 in decline of immediate memory.
Researchers found that individuals with frontotemporal dementia were physically aggressive earlier and exhibited more severe behavior towards strangers compared to those with Alzheimer's disease. The study of 281 deceased patients revealed a significant difference in the manifestation of aggression between the two groups.
A new study has demonstrated the potential of using a frequency distribution-based index of brain functional connectivity as a biomarker for detecting Alzheimer's disease and mild cognitive impairment. The findings show good accuracy across databases and test sites, offering promise for widespread clinical usage.
Researchers found that intermittent electrical stimulation improved working memory in adult non-human primates, whereas continuous deep brain stimulation impaired memory. The study suggests that increased acetylcholine levels and blood flow may contribute to the benefits of intermittent stimulation.
A team of researchers has determined the structure of an amyloid fibril with unprecedented resolution, revealing new details on its growth and effect of genetic risk factors. The atomic-level three-dimensional structure displays how Aβ protein molecules are staggered in layers to form protofilaments.